trending Market Intelligence /marketintelligence/en/news-insights/trending/3_wqhwuqni5c3xfkvz879w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

DiaMedica raises $3.8M via placement to fund trial for stroke treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

DiaMedica raises $3.8M via placement to fund trial for stroke treatment

Minneapolis' DiaMedica Therapeutics Inc. raised gross proceeds of $3.8 million through a private placement of units.

The biopharmaceutical company issued 15,955,225 units at 24.5 cents each in the placement's first closing. Each unit comprises 1 common share and 0.5 of a 24-month warrant to buy an additional share for 35 cents.

DiaMedica expects to close the placement's second tranche on or about March 27.

The company plans to use net proceeds to fund a trial, called Remedy, evaluating DM199 to treat acute ischemic stroke. Proceeds will also go toward general corporate purposes.

Dominick Capital Corp. is acting as lead agent for the private placement, with Echelon Wealth Partners Inc., Canaccord Genuity Corp., Richardson GMP Ltd., Leede Jones Gable and Mackie Research Capital Corp. as finders.